Sensible biotechnologies announces partnership with ginkgo bioworks to develop novel mrna manufacturing platform

Through this partnership, sensible and ginkgo aim to develop an in vivo alternative to conventional in vitro mrna production technology oxford, united kingdom , april 3, 2023 /prnewswire/ -- sensible biotechnologies, an early stage biotechnology company, today announced a partnership to develop an in vivo microbial mrna manufacturing platform with ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity. today, the vast majority of mrna used in vaccines, therapeutics and other applications is produced by in vitro transcription (ivt), a cell-free process, which is driven by purified enzymes.
DNA Ratings Summary
DNA Quant Ranking